Cargando…

TMB in NSCLC: A Broken Dream?

Although immune checkpoint inhibitors have changed the treatment paradigm of a variety of cancers, including non-small-cell lung cancer, not all patients respond to immunotherapy in the same way. Predictive biomarkers for patient selection are thus needed. Tumor mutation burden (TMB), defined as the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bravaccini, Sara, Bronte, Giuseppe, Ulivi, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234326/ https://www.ncbi.nlm.nih.gov/pubmed/34207126 http://dx.doi.org/10.3390/ijms22126536

Ejemplares similares

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC
por: Křížová, Ľudmila, et al.
Publicado: (2022)

What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Emergency surgery, acute care surgery and the boulevard of broken dreams
por: Catena, Fausto, et al.
Publicado: (2009)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
por: Pasini, Luigi, et al.
Publicado: (2019)

Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB
por: Fridland, Stanislav, et al.
Publicado: (2021)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Identifying Inconsistencies and Reporting Deficits in Therapeutic Massage and Bodywork (TMB) Case Reports Authored by TMB Practitioners: a TMB-Adapted CAse REport (CARE) Guidelines Audit Through 2014
por: Munk, Niki, et al.
Publicado: (2016)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

My Child Redeems My Broken Dreams: On Parents Transferring Their Unfulfilled Ambitions onto Their Child
por: Brummelman, Eddie, et al.
Publicado: (2013)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
por: Bronte, Giuseppe, et al.
Publicado: (2023)

Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)
por: Ma, Xiaoting, et al.
Publicado: (2021)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

Spotlight on dream recall: the ages of dreams
por: Mangiaruga, Anastasia, et al.
Publicado: (2018)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

Coleridge on dreaming: romanticism, dreams, and the medical imagination
por: Rousseau, G S
Publicado: (2000)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

ecTMB: a robust method to estimate and classify tumor mutational burden
por: Yao, Lijing, et al.
Publicado: (2020)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
por: De Matteis, Serena, et al.
Publicado: (2019)

Broken dreams of a better life in Sweden: Thai women’s lived experiences of intimate partner violence by Swedish men in international marriages
por: Pongthippat, Weerati, et al.
Publicado: (2018)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer
por: Zhao, Yan, et al.
Publicado: (2023)

The World of Dreams
Publicado: (1912)

The Interpretation of Dreams
Publicado: (1914)

Dream Psychology
Publicado: (1919)

On Broken Ne(c)ks and Broken DNA: The Role of Human NEKs in the DNA Damage Response
por: Pavan, Isadora Carolina Betim, et al.
Publicado: (2021)

“Broken Heart” and “Broken Brain”: Which Connection?
por: Papadis, Athanasios, et al.
Publicado: (2022)

A dream within a dream
por: Kamsani, Suraya H., et al.
Publicado: (2023)

The Language of Dreams: Application of Linguistics-Based Approaches for the Automated Analysis of Dream Experiences
por: Elce, Valentina, et al.
Publicado: (2021)

Dream-Thought and Dream-Life
Publicado: (1862)

Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC
por: Ulivi, Paola, et al.
Publicado: (2013)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
por: Hodi, F. Stephen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i9cftd09rfa7gei4ohirhbim9c